MedRegen will initiate a phase 2a randomized, double-blind placebo-controlled multi-center study in hospitalized patients infected with severe and critical SARS-CoV-2 to assess the safety, pharmacokinetics and pharmacodynamics and efficacy of MRG-001. The trial will include 40 patients, 20 placebo and 20 MRG-001 treated. An interim analysis will take place after the first 40 patients have been included, to assess safety and tolerability with the option for sample size reestimation and determining a primary endpoint for the study.
For more details on the clinical trial, please visit: MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 patients.